Plain-English translation of NCT06600802 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying whether analyzing the genetic makeup of your prostate cancer tumor can predict how well you'll respond to 177Lutetium-PSMA-617, a newer radioactive treatment for advanced prostate cancer. This medication has shown promise, but about 4 in 10 patients don't respond to it. By looking at the molecular characteristics of your tumor, doctors hope to identify which patients are most likely to benefit from this treatment.
Currently, there's no reliable way to know in advance which patients will respond well to this medication and which won't. Identifying genetic biomarkers could help doctors make better treatment decisions and avoid giving ineffective therapy to patients who won't benefit from it.
You likely qualify if…
You likely don't qualify if…
If you qualify, researchers will use tumor tissue that was already collected during your previous biopsy or surgery—you won't need additional biopsies for this study. They will perform genetic and molecular analysis on this tissue to identify biomarkers. You will receive the newer treatment (177Lutetium-PSMA-617) as planned, and the study will track how well the genetic markers predict your treatment response over time. The primary involvement is allowing your existing tumor samples to be analyzed for research purposes.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
France